Evidence map›Paper›PMID 38837275›Full record

ArticleJournal of viral hepatitis2024

Network-based strategies to combat HCV: Examining social and spatial drivers of transmission among PWID in New Delhi.

Steven J Clipman, Shruti H Mehta, Shobha Mohapatra, Aylur K Srikrishnan, Katie J C Zook, Muniratnam Suresh Kumar, Gregory M Lucas, Carl A Latkin, Sunil S Solomon

Abstract read
In one paragraph

Article in Journal of viral hepatitis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Steven J ClipmanDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0002-2366-8420
Shruti H MehtaDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Shobha MohapatraYR Gaitonde Centre for AIDS Research and Education (YRGCARE), Chennai, India.
Aylur K SrikrishnanYR Gaitonde Centre for AIDS Research and Education (YRGCARE), Chennai, India.
Katie J C ZookDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Muniratnam Suresh KumarYR Gaitonde Centre for AIDS Research and Education (YRGCARE), Chennai, India.
Gregory M LucasDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Carl A LatkinDepartment of Health, Behavior, and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Sunil S SolomonDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
Strategies to improve the HIV care continuum among key populations in IndiaR01DA041034 · NIDA · JOHNS HOPKINS UNIVERSITY · PI LUCAS, GREGORY M, MEHTA, SHRUTI H · 2015 to 2021
$6.7M
Individual, Network and Spatial Drivers of HIV and HCV among PWID in IndiaR01DA041736 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SOLOMON, SUNIL SUHAS · 2016 to 2021
$5.0M
Reaching the hardest of the hard-to-reachDP2DA040244 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SOLOMON, SUNIL SUHAS · 2016 to 2023
$2.8M
Molecular Networks and Deep Learning for Targeted HIV Interventions among PWIDDP2DA056130 · NIDA · JOHNS HOPKINS UNIVERSITY · PI CLIPMAN, STEVEN J. · 2022 to 2022
$2.5M
Treatment outcomes and comorbidity in HIV-infected IDUK24DA035684 · NIDA · JOHNS HOPKINS UNIVERSITY · PI LUCAS, GREGORY M · 2014 to 2024
$1.5M
Center for AIDS Research, Johns Hopkins UniversityNIAID NIH HHS P30 AI094189NIDA NIH HHS DP2 DA040244NIDA NIH HHS DP2 DA056130NIDA NIH HHS K24 DA035684NIDA NIH HHS L60 DA056996NIDA NIH HHS R01 DA041034NIDA NIH HHS R01 DA041736
6 · The paper itself

Abstract

People who inject drugs (PWID) account for some of the fastest-growing HCV epidemics globally. While individual risk factors for infection are understood, less is known about network and spatial factors critical for elimination strategies. Two thousand five hundred twelve PWID in New Delhi, India, were recruited (2017-19) through network referrals. Biometrics identified duplicates and cross-network linkages. Participants completed semi-annual surveys and blood tests for HCV antibodies and RNA. Poisson regression and network analyses identified predictors of incident HCV and compared network-based intervention approaches. Baseline HCV antibody prevalence was 65.1%, of whom 79.6% were HCV RNA-positive. We observed 92 HCV seroconversions over 382.25 person-years (incidence: 24.1 per 100 person-years). Of the 92 seroconverters, 67% (62) were directly connected to an RNA-positive participant, and all were within one degree of separation from an RNA-positive participant. Individual-level factors associated with seroconversion included age, sexual activity, and injection behaviours. After adjusting for individual-level factors, seroconversion was significantly associated with number of RNA-positive partners (adjusted incidence rate ratio [AIRR] = 1.30) and injecting at a particular venue (AIRR = 2.53). This association extended to indirect ties, with 17% reduced odds of seroconversion for each degree of separation from the venue (AIRR = 0.83). Network analyses comparing intervention strategies found that targeting venues identified more cases compared to a treat-a-friend approach. We observed a fast-growing HCV epidemic driven by viremia within individuals' immediate networks and indirect social and spatial ties, demonstrating the importance of achieving broad, sustained virologic response and rethinking network-based interventions to include venues.

Indexed as

Hepatitis CHepatitis C AntibodiesSubstance Abuse, IntravenousAdultFemaleHepacivirusHumansIncidenceIndiaMaleMiddle AgedPrevalenceRisk FactorsRNA, ViralSeroconversionYoung AdultHepatitis C AntibodiesRNA, ViralIndiapeople who inject drugssociometric networktransmission dynamics

Identifiers

PMID38837275
PMCPMC11480898

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.